Brought to you by:
In wake of President Trump’s chronic venous insufficiency diagnosis, SVS steps up to educate public
News that U.S. President Donald J. Trump has a vascular condition may have simultaneously revealed that a substantial seven-figure vascular surgery branding campaign was starting to yield tangible results, and provided a singular opportunity to platform the specialty as the…
One-year data from VenoValve US pivotal trial emerges
Envveno Medical has announced that it will present one-year data on all patients from the VenoValve US pivotal trial today at the VEITHsymposium (19–23 November, New York, USA). The definitive one-year data support the application submitted earlier this week by Envveno Medical seeking…
Prosthetic valve implantation shows “vast” improvements in deep chronic venous insufficiency
“The surgical challenges of repairing deep venous reflux have been present for more than a generation. It is worth reflecting on the fact that this new technology has made the majority of patients vastly better,” were the words of principal…
First-in-human patients continue to benefit from VenoValve at average of three years post-surgery, new data show
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently presented at the VEITHsymposium 2022 (Nov. 15–19) in New York City. Principal investigator Jorge Hernando Ulloa, MD,…
AVF 2022: Emerging autogenous venous valve formation system sees ‘continual improvement’
An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual improvement since U.S. investigators started performing clinical cases with the device 18 months ago, according to…